D. E. Shaw & Co., Inc. Bei Gene, Ltd. Put Options Transaction History

D. E. Shaw & Co., Inc.

5 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q2 2022 Aug 15, 2022	SELL	$121.11 - $216.05 $1.21 Million - $2.16 Million	-10,000 Closed	0 $0
Q1 2022 May 16, 2022	BUY	$146.52 - $269.56 $1.47 Million - $2.7 Million	10,000 New	10,000 $1.89 Million
Q1 2019 May 15, 2019	SELL	$122.82 - $151.83 $3.07 Million - $3.8 Million	-25,000 Closed	0 $0
Q3 2018 Nov 14, 2018	BUY	$152.62 - $189.66 $2.29 Million - $2.84 Million	15,000 Added 150.0%	25,000 $4.31 Million
Q4 2017 Feb 14, 2018	BUY	$79.6 - $114.73 $796,000 - $1.15 Million	10,000	10,000 $977,000

254

45.3M

292K

119K

Ticker BGNE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 103,700,000
Market Cap $23.5B
Description
BeiGene, Ltd., a biotechnology company, focuses on discovering, developing, manufacturing, and commercializing various medicines worldwide. Its products include BRUKINSA to treat relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin's lymphoma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplas...

Get notified when there are updates to the investment portfolio of D. E. Shaw & Co., Inc., based on Form 13F filings with the SEC.

Stay updated on D. E. Shaw & Co., Inc. with notifications on news.